Several considerations have been proposed, such as choosing a dose range with few adverse effects and adequate anti-tumor potency, developing a distribution-restricted CAR T-cell that kills tumor cells locally, and enhancing the scFv affinity so that CAR T-cells can only be stimulated by the high density of EpCAM protein on the surface of tumor cells but not on healthy cells (101). The gene discussed is EPCAM; the disease is neoplasm.